A subset of patients taking ibrutinib as a therapy for chronic lymphocytic leukemia (CLL) will require dose modifications. A new study attempts to evaluate the impacts of such changes, though the ...
IMBRUVICA plus rituximab showed significant improvement in progression-free survival versus rituximab monotherapy in Waldenström's macroglobulinemia, a rare blood cancer TORONTO, March 8, 2019 /CNW/ - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback